NASI North American Scientific (MM)

North American Scientific, Inc. (Nasdaq:NASI) announced today that it will issue financial results for the second fiscal quarter of 2007, which ended April 30, 2007, at market close on Monday, June 4, 2007. John Rush, President and Chief Executive Officer, Michael Cutrer, Executive Vice President and Chief Technology Officer, and Jim Klingler, Senior Vice President and Chief Financial Officer, will host an investor conference call to review the Company�s second quarter 2007 financial results and latest corporate developments, beginning at 1:30 p.m. PDT/4:30 p.m. EDT on Monday, June 4, 2007. The dial-in number for the conference call is 800-218-0204 for domestic participants and 303-262-2142 for international participants. A live webcast of North American Scientific's conference call will be available over the Internet through its website at www.nasmedical.com in the Investor Center. For those who cannot listen to the live webcast, a taped replay of the call will be available beginning approximately one hour after the call�s conclusion and will remain available for seven days. It can be accessed at the same site shortly after the call, or by dialing 800-405-2236 for domestic callers and 303-590-3000 for international callers, using the passcode 11090365#. About North American Scientific North American Scientific is a leader in radiation therapy products and services in the fight against cancer. Its innovative products provide physicians with tools for the treatment of various types of cancers. They include Prospera� brachytherapy seeds and SurTRAK� needles and strands used primarily in the treatment of prostate cancer. In addition the Company plans to commercialize its ClearPath� multi-channel catheter breast brachytherapy devices in 2007, which are the only devices approved for both high dose and continuous release, or low dose, radiation treatments. The devices are designed to provide flexible, precise dose conformance and an innovative delivery system that is intended to offer the more advanced form of brachytherapy for the treatment of breast cancer. North American Scientific also provides external beam radiation therapy products for Serial Tomotherapy Intensity Modulated Radiation Therapy (IMRT) and Image-Guided Radiation Therapy (IGRT). Serial tomotherapy IMRT allows an escalated radiation dose to be delivered to a tumor while limiting exposure and damage to nearby healthy tissue. These products are marketed under the trade names nomosSTAT�and CORVUS� (our proprietary treatment planning software). The Company's IGRT products, BAT�, BATCAM� and nTRAK�, provide fast and accurate targeting and localization of a treatment volume on a daily basis. More than 500 hospitals and research sites worldwide are equipped with the Company's clinically proven serial tomotherapy, inverse treatment planning, image-guidance and ancillary treatment solutions. Please visit www.nasmedical.com for more information. Statements included in this release that are not historical facts may be considered forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company including, but not limited to, the impact of competitive products and pricing, technological changes, changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements, the ability of the Company to successfully directly market and sell its products, uncertainties relating to patent protection and regulatory approval, the stable supply of appropriate isotopes, research and development estimates, market opportunities, risks associated with strategic opportunities or acquisitions the Company may pursue and the risk factors included in the Company�s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this news release speak only as of the date of this release, and the Company undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future results or otherwise.